Pancreatic Cancer Research

ResearcherNihon UniversityActive in the last 2 years

Yukiyasu Okamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3384-2709; OpenAlex author ID A5036182057. Sources: OpenAlex.

Their work

Papers
36 (first author 6, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 4 papers · 2021: 8 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 5 papers

Papers 36

  1. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  2. Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy. Co-author DOI 10.1097/sla.0000000000007152↗
  3. Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. Co-author DOI 10.1245/s10434-025-18556-3↗
  4. ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18624-8↗
  5. ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. First author DOI 10.1245/s10434-026-19112-3↗
  6. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  7. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. Co-author DOI 10.1093/bjs/znae059↗
  8. Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. Co-author DOI 10.1002/ags3.12636↗
  9. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology. Co-author DOI 10.1007/s00423-023-02906-4↗
  10. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  11. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Co-author DOI 10.1016/j.pan.2022.03.017↗
  12. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Co-author DOI 10.1245/s10434-022-11624-y↗
  13. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologic… Co-author DOI 10.1245/s10434-022-11639-5↗
  14. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy. First author DOI 10.1007/s00535-020-01730-7↗
  15. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13304-020-00792-9↗
  16. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. First author DOI 10.1016/j.pan.2021.08.009↗
  17. Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001848↗
  18. Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09066-5↗
  19. Clinical Implication of Node-negative Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09543-x↗
  20. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. First author DOI 10.1245/s10434-021-09593-9↗
  21. ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients. First author DOI 10.1245/s10434-021-09660-1↗
  22. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. Co-author DOI 10.1007/s00423-020-01874-3↗
  23. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01970-4↗
  24. Middle segment-preserving pancreatectomy for multifocal pancreatic ductal adenocarcinoma located in the head and tail of the pancreas: a case report. Co-author DOI 10.1093/jscr/rjaa383↗
  25. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  26. Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer. Co-author DOI 10.1002/bjs.11328↗
  27. A case of pancreatic cancer invading the superior mesenteric artery causing extensive intestinal necrosis that was successfully treated by surgery. Co-author DOI 10.1093/jscr/rjz118↗
  28. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  29. Microscopic Venous Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6324-2↗
  30. Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma. First author DOI 10.1007/s00268-017-4027-2↗
  31. The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2017.03.001↗
  32. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  33. Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-014-4046-2↗
  34. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Last author DOI 10.1016/j.surg.2013.04.015↗
  35. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma. Last author DOI 10.1245/s10434-013-3227-8↗
  36. [Postoperative adjuvant treatment for pancreatic cancer: present status and future perspective]. Co-author PMID 21918335↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katsuhiko Uesaka · 33 shared papers, 2011–2026 · strength 4.02
  2. Teiichi Sugiura · 29 shared papers, 2011–2026 · strength 3.84
  3. Ryo Ashida · 25 shared papers, 2017–2026 · strength 3.70
  4. Katsuhisa Ohgi · 21 shared papers, 2019–2026 · strength 3.09
  5. Takaaki Ito · 15 shared papers, 2017–2022 · strength 1.74
  6. Taisuke Imamura · 9 shared papers, 2019–2024 · strength 1.25
  7. Keiichi Ohshima · 5 shared papers, 2023–2026 · strength 1.20
  8. Yuya Miura · 5 shared papers, 2022–2026 · strength 1.14
  9. Mihoko Yamada · 6 shared papers, 2018–2024 · strength 0.89
  10. Akira Fukutomi · 8 shared papers, 2016–2026 · strength 0.85
  11. Soichiro Morinaga · 6 shared papers, 2016–2026 · strength 0.69
  12. Kenichi Urakami · 3 shared papers, 2024–2026 · strength 0.67
  13. Narikazu Boku · 5 shared papers, 2016–2026 · strength 0.53
  14. Akiko Todaka · 4 shared papers, 2019–2023 · strength 0.51
  15. Ken D Yamaguchi · 2 shared papers, 2024–2026 · strength 0.43
  16. Amane Takahashi · 3 shared papers, 2020–2026 · strength 0.43
  17. Hirochika Toyama · 3 shared papers, 2020–2026 · strength 0.43
  18. Mitsuro Kanda · 1 shared paper, 2026 · strength 0.39
  19. Masamichi Hayashi · 1 shared paper, 2026 · strength 0.39
  20. Keizo Fujita · 1 shared paper, 2026 · strength 0.39
  21. Atsuyuki Maeda · 2 shared papers, 2022–2026 · strength 0.34
  22. Shoji Nakamori · 4 shared papers, 2016–2022 · strength 0.30
  23. Naohiro Sata · 4 shared papers, 2016–2022 · strength 0.30
  24. Yusuke Yamamoto · 2 shared papers, 2021 · strength 0.27
  25. Ippei Matsumoto · 3 shared papers, 2016–2024 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.